Hepatitis C Treatment Options

Once a person has had the diagnosis confirmed that they are infected with Hepatitis C there are treatment options that must be considered. At one time it was believed that if the infection was still in its acute stage, meaning the person had been infected for less then six months, no treatment should be used. Physicians hoped that if left alone it would go away. So they did nothing. Research has changed this analysis.  Now they work vigorously through all stages of Hepatitis C to do the best they can to treat the infection. But the kind of treatment they offer depends a lot on what age the patient is more than just the stage of infection that they are in.

A child will be given a treatment of interferon with no accompanying medication. If they are still in the acute stage the success rate is seventy percent.  Though researchers are still trying to understand why this treatment works so well in children parents are grateful for the high success rate. There is more confusion in treating children than in adults.  Studies are continuing to better understand why a higher portion of children can clear the infection out of there systems without treatment than adults can.

Seniors are another treatment issue. When someone over sixty becomes infected physicians do not suggest using any treatment.  This is because the progress of Hepatitis C to serious liver damage, cirrhosis of the liver, can take anywhere from twenty to forty years. Therefore it is felt that a person of that age will more likely die of natural causes in their old age than anything connected with the Hepatitis C virus.  There will be some common sense lifestyle changes but beyond that more regular check-ups are about all that needs to be done.

Anyone who does not fall into those age restrictions has more treatment options. Interferon is the medication used most often to treat the Hepatitis C virus.  Use of this medication alone has a cure rate of twenty five percent. That means the infection comes under control.  Unfortunately sometimes patients have a relapse and if so this calls for a drug therapy that combines interferon with ribavirin.  This double hitting drug therapy has some good results with forty five percent of patients using this combination showing diminished levels of the virus. Neither of these should be used if a woman is pregnant as it can cause defects or death of the fetus. Don't let the side effects prevent you from taking the treatment.

Anyone who is being treated for Hepatitis C should do a few things to help their health.  One of the most important is to stop drinking. Alcohol will only speed along the damage to a person's liver. Do not use any new over the counter medications or try any natural or herbal remedies without first talking to your health care provider. Ask about getting vaccinated for both Hepatitis A nd B, especially if there are already some signs of liver damage.

Hepatitis news on the Web

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Sciences jumps on hepatitis C dataCBS News
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
Gilead shares surge as hep C drug scores a cure for big patient populationFierceBiotech
Lagonian.com -Barron's (blog)
all 63 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge
Scientists establish HCV infection in liver-like cells derived from iPSCsNews-Medical.net

all 5 news articles »

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
FDA removes hold on Idenix hep C drug targetMass High Tech
NASDAQ -PR Newswire (press release)
all 31 news articles »

HP awards Meg Whitman $16.5 million pay package - San Francisco Chronicle

HP awards Meg Whitman $16.5 million pay package
San Francisco Chronicle
Gilead's shares rose 11 percent on news a hepatitis C drug showed positive results in clinical trials. Gilead Sciences, the Foster City drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in ...

and more »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
Vertex Falls as analyst cuts sales estimates on hepatitis C pillBoston Globe
LocalizedUSA
all 15 news articles »

Prosecutor says doctor in hepatitis C outbreak is faking disabilities. - Las Vegas Review - Journal

Washington Examiner

Prosecutor says doctor in hepatitis C outbreak is faking disabilities.
Las Vegas Review - Journal
Desai, 62, is challenging state medical experts who found him competent to stand trial on criminal charges in the 2007 hepatitis C outbreak. » Buy this photo By Jeff German Dr. Dipak Desai, the physician at the center of the hepatitis C outbreak, ...
Judge: Dipak Desai competent to stand trial in hepatitis caseLas Vegas Sun
Desai found competent to stand trialLas Vegas Review-Journal
Ex-doc ruled fit for trial in Vegas hep C caseWashington Examiner

all 15 news articles »

researchers identify peptide that inhibits replication of hepatitis C - UC Los Angeles

researchers identify peptide that inhibits replication of hepatitis C
UC Los Angeles
By Kim Irwin February 02, 2012 Category: Health Sciences, Research Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks the viral replication that can ...

and more »

March trial for Desai may be postponed again - Las Vegas Review - Journal

March trial for Desai may be postponed again
Las Vegas Review - Journal
Buy this photo By Jeff German Dr. Dipak Desai may have been found competent to face criminal charges in the hepatitis C outbreak, but his upcoming March 12 trial is expected to be delayed again. Lawyers on both sides of the massive criminal case do not ...
FOX5 Vegas - KVVUDipak Desai found mentally fit to stand trialKVVU Las Vegas
Ex-doc ruled fit for trial in Vegas hepatitis-C caseMyNews3

all 5 news articles »

Vertex posts 4Q profit on growing Incivek sales - CBS News

Vertex posts 4Q profit on growing Incivek sales
CBS News
Drugmaker Vertex Pharmaceuticals Inc. said Thursday it turned a profit in the fourth quarter on sales of its hepatitis C pill Incivek, which was approved in May. Vertex reported a profit of $158.6 million, or 74 cents per share.
Curing Diseases Makes For a Bad Business ModelDailyFinance
Vertex roiled by fickle marketBizjournals.com
Vertex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call TranscriptSeeking Alpha
Zacks.com
all 21 news articles »

Stem Cells May Further Hepatitis C Research - U.S. News & World Report

Stem Cells May Further Hepatitis C Research
U.S. News & World Report
31 (HealthDay News) -- Using stem cells to create liver-like cells for laboratory research may advance efforts to find out why people respond differently to hepatitis C infection, scientists say. It's not clear why some people are resistant to ...

and more »


Google News